AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV prevention drug, lenacapavir.

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

PhRMA said in a January submission to the US trade review that US companies were the “constant target of compulsory licensing ...

Gilead's lenacapavir approval by the US Food and Drug Administration (FDA) marks a milestone in HIV prevention, but experts warn over its expense. Sophie Cousins reports.

HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to ...

Likewise, earlier Special 301 Reports vociferously condemned a practice known as compulsory licensing, which is when, under certain circumstances, a foreign government allows a business to ...

Quality information is even more important now in an age of AI slop where the information ecosystem is awash in misleading images and strange blah words that sound like they mean something but don’t ...

Australian patent law includes mechanisms intended to address these concerns, but their effectiveness is questionable. Section 133 of the Patents Act permits compulsory licensing if reasonable ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

Pharma industry bodies have slammed a proposal by the European Commission to set up a compulsory licensing (CL) framework for medicines in emergency situations, claiming there is no need for the move.

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.